Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Alzheimer's disease agitation/psychosis(Stage not disclosed)
Negative symptoms of schizophrenia(Stage not disclosed)
Catalysts
— second half of 2027
Status note First benzamide antipsychotic for neuropsychiatric disorders. Pivotal Phase 3 NOVA-2 in schizophrenia (concurrent open-label outpatient NOVA-3 enrolling); Phase 2 ILLUMINATE-1 in bipolar depression; Phase 2 in adjunctive MDD; additional expansion planned in negative symptoms of schizophrenia and Alzheimer's agitation/psychosis.
Status note Long-acting injectable formulation of LB-102 under development to improve adherence.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.